Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection

ACS Chemical Biology

Volumn 4, Issue 11, 2009, Pages 928-938

  Cremades, Nunilo ^a   Velázquez Campoy, Adrián ^a,b   Martínez Júlvez, Marta ^a   Neira, José L ^a,c   Pérez Dorado, Inmaculada ^d   Hermoso, Juan ^d   Jiménez, Pilar ^a   Lanas, Angel ^a   Hoffman, Paul S ^e   Sancho, Javier ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b FUNDACIÓN ARAID   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; FLAVODOXIN; FLAVODOXIN INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BACTERICIDAL ACTIVITY; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; ENZYMATIC ASSAY; HELA CELL; HELICOBACTER INFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; STRUCTURE ANALYSIS; THERMODYNAMICS;

ANIMALS; ANTI-BACTERIAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ELECTRON TRANSPORT; FLAVODOXIN; HELA CELLS; HELICOBACTER INFECTIONS; HUMANS; MICE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

HELICOBACTER PYLORI; MUS;

EID: 73449083030     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb900166q     Document Type: Article

References (44)

1. Marshall, B. J., and Warren, J. R. (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration, Lancet 1, 1311-1315.
2. Wotherspoon, A. C., Doglioni, C., Diss, T. C., Pan, L., Moschini, A., de Boni, M., and Isaacson, P. G. (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori, Lancet 342, 575-577.
3. Parsonnet, J., Hansen, S., Rodriguez, L., Gelb, A. B., Warnke, R. A., Jellum, E., Orentreich, N., Vogelman, J. H., and Friedman, G. D. (1994) Helicobacter pylori infection and gastric lymphoma, N. Engl. J. Med. 330, 1267-1271.
4. Parsonnet, J., Friedman, G. D., Vandersteen, D. P., Chang, Y., Vogelman, J. H., Orentreich, N., and Sibley, R. K. (1991) Helicobacter pylori infection and the risk of gastric carcinoma, N. Engl. J. Med. 325, 1127-1131.
5. Bruce, M. G., and Maaroos, H. I. (2008) Epidemiology of Helicobacter pylori infection, Helicobacter 13, 1-6.
6. Wilson, K. T., and Crabtree, J. E. (2007) Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies, Gastroenterology 133, 288-308.
7. Agarwal, K., and Agarwal, S. (2008) Helicobacter pylori vaccine: from past to future, Mayo Clin. Proc. 83, 169-175.
8. Seppala, K., and Nuutinen, H. (1995) New options in eradication of Helicobacter pylori, Ann. Med. 27, 601-604.
9. Adamek, R. J., Suerbaum, S., Pfaffenbach, B., and Opferkuch, W. (1998) Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome, Am. J. Gastroenterol. 93, 386-389.
10. Glupczynski, Y. (1998) Antimicrobial resistance in Helicobacter pylori: a global overview, Acta Gastroenterol. Belg. 61, 357-366.
11. Ferrero, M., Ducons, J. A., Sicilia, B., Santolaria, S., Sierra, E., and Gomollon, F. (2000) Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period, Int. J. Antimicrob. Agents 16, 245-248.
12. Wu, J. Y., Kim, J. J., Reddy, R., Wang, W. M., Graham, D. Y., and Kwon, D. H. (2005) Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes, Antimicrob. Agents Chemother. 49, 578-583.
13. Carothers, J. J., Bruce, M. G., Hennessy, T. W., Bensler, M., Morris, J. M., Reasonover, A. L., Hurlburt, D. A., Parkinson, A. J., Coleman, J. M., and McMahon, B. J. (2007) The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection, Clin. Infect. Dis. 44, e5-8.
14. Graham, D. Y., and Shiotani, A. (2008) New concepts of resistance in the treatment of Helicobacter pylori infections, Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 321-331.
15. Mégraud, F. (2004) Basis for the management of drug-resistant Helicobacter pylori infection, Drugs 64, 1893-1904.
16. Chalker, A. F., Minehart, H. W., Hughes, N. J., Koretke, K. K., Lonetto, M. A., Brinkman, K. K., Warren, P. V., Lupas, A., Stanhope, M. J., Brown, J. R., and Hoffman, P. S. (2001) Systematic identification of selective essential genes in Helicobacter pylori by genome prioritization and allelic replacement mutagenesis, J. Bacteriol. 183, 1259-1268.
17. Freigang, J., Diederichs, K., Schafer, K. P., Welte, W., and Paul, R. (2002) Crystal structure of oxidized flavodoxin, an essential protein in Helicobacter pylori, Protein Sci. 11, 253-261.
18. Cremades, N., Bueno, M., Toja, M., and Sancho, J. (2005) Towards a new therapeutic target: Helicobacter pylori flavodoxin, Biophys. Chem. 115, 267-276.
19. Sancho, J. (2006) Flavodoxins: sequence, folding, binding, function and beyond, Cell. Mol. Life Sci. 63, 855-864.
20. Hughes, N. J., Chalk, P. A., Clayton, C. L., and Kelly, D. J. (1995) Identification of carboxylation enzymes and characterization of a novel four-subunit pyruvate:flavodoxin oxidoreductase from Helicobacter pylori, J. Bacteriol. 177, 3953-3959.
21. St Maurice, M., Cremades, N., Croxen, M. A., Sisson, G., Sancho, J., and Hoffman, P. S. (2007) Flavodoxin:Quinone Reductase (FqrB): a redox partner of pyruvate:ferredoxin oxidoreductase that reversibly couples pyruvate oxidation to NADPH production in Helicobacter pylori and Campylobacter jejuni, J. Bacteriol. 189, 4764-4773.
22. Baker, L. M., Raudonikiene, A., Hoffman, P. S., and Poole, L. B. (2001) Essential thioredoxin-dependent peroxiredoxin system from Helicobacter pylori: genetic and kinetic characterization, J. Bacteriol. 183, 1961-1973.
23. Pace, C. N., and McGrath, T. (1980) Substrate stabilization of lysozyme to thermal and guanidine hydrochloride denaturation, J. Biol. Chem. 255, 3862-3865.
24. Brandts, J. F., and Lin, L. N. (1990) Study of strong to ultratight protein interactions using differential scanning calorimetry, Biochemistry 29, 6927-6940.
25. Straume, M., and Freire, E. (1992) Two-dimensional differential scanning calorimetry: simultaneous resolution of intrinsic protein structural energetics and ligand binding interactions by global linkage analysis, Anal. Biochem. 203, 259-268.
26. Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., and Salemme, F. R. (2001) High-density miniaturized thermal shift assays as a general strategy for drug discovery, J. Biomol. Screening 6, 429-440.
27. Lo, M. C., Aulabaugh, A., Jin, G., Cowling, R., Bard, J., Malamas, M., and Ellestad, G. (2004) Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery, Anal. Biochem. 332, 153-159.
28. Senisterra, G. A., Markin, E., Yamazaki, K., Hui, R., Vedadi, M., and Awrey, D. E. (2006) Screening for ligands using a generic and high-throughput light-scattering-based assay, J. Biomol. Screening 11, 940-948.
29. Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., Maguire, D., Lattanze, J., Franks, C. F., Zhao, S., Ramachandren, K., Bylebyl, G. R., Zhang, M., Manthey, C. L., Petrella, E. C., Pantoliano, M. W., Deckman, I. C., Spurlino, J. C., Maroney, A. C., Tomczuk, B. E., Molloy, C. J., and Bone, R. F. (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells, J. Med. Chem. 48, 909-912.
30. Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor, Biochemistry. 44, 5258-5266.
31. Pey, A. L., Ying, M., Cremades, N., Velazquez-Campoy, A., Scherer, T., Thony, B., Sancho, J., and Martinez, A. (2008) Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria, J. Clin. Invest. 118, 2858-2867.
32. Tucker, C. L. (2002) High-throughput cell-based assays in yeast, Drug Discovery Today 7, S125-130.
33. Cremades, N., Velazquez-Campoy, A., Freire, E., and Sancho, J. (2008) The flavodoxin from Helicobacter pylori: structural determinants of thermostability and FMN cofactor binding, Biochemistry 47, 627-639.
34. Hoffman, P. S., Sisson, G., Croxen, M. A., Welch, K., Harman, W. D., Cremades, N., and Morash, M. G. (2007) Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori and selected anaerobic bacteria and parasites, and Campylobacter jejuni, Antimicrob. Agents Chemother. 51, 868-876.
35. Piccolomini, R., Di Bonaventura, G., Picciani, C., Laterza, F., Vecchiet, J., and Neri, M. (2001) In vitro activity of clarithromycin against intracellular Helicobacter pylori, Antimicrob. Agents Chemother. 45, 1568-1571.
36. Fotakis, G., and Timbrell, J. A. (2006) In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride, Toxicol. Lett. 160, 171-177.
37. Abraham, V. C., Towne, D. L., Waring, J. F., Warrior, U., and Burns, D. J. (2008) Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans, J. Biomol. Screening 13, 527-537.
38. Kover, K. E., Groves, P., Jimenez-Barbero, J., and Batta, G. (2007) Molecular recognition and screening using a 15N group selective STD NMR method, J. Am. Chem. Soc. 129, 11579-11582.
39. Cremades, N., Bueno, M., Neira, J. L., Velazquez-Campoy, A., and Sancho, J. (2008) Conformational stability of Helicobacter pyloriflavodoxin: fit to function at pH 5, J. Biol. Chem. 283, 2883-2895.
40. Sisson, G., Goodwin, A., Raudonikiene, A., Hughes, N. J., Mukhopadhyay, A. K., Berg, D. E., and Hoffman, P. S. (2002) Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori, Antimicrob. Agents Chemother. 46, 2116-2123.
41. Mayhew, S. G., and Massey, V. (1969) Purification and characterization of flavodoxin from Peptostreptococcus elsdenii, J. Biol. Chem. 244, 794-802.
42. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Delivery Rev. 46, 3-26.
43. McGregor, M. J., and Pallai, P. V. (1997) Clustering of large databases of compounds: using the MDL "keys" as structural descriptors, J. Chem. Inf. Comput. Sci. 37, 443-448.
44. Privalov, P. L. (1979) Stability of proteins: small globular proteins, Adv. Protein Chem. 33, 167-241.